Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × sintilimab × Gynecologic × Clear all

Phase

Phase 2 5 Phase NA 1 Phase 3 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7 Thoracic 1 Other solid neoplasm 1 Gynecologic 1

Conditions

Endometrial Neoplasms 1

Interventions

Paclitaxel 9 Carboplatin 8 liposomal doxorubicin 5 Drug Therapy 5 Cisplatin 5 Topotecan 3 Megestrol Acetate 3 Letrozole 3 Bevacizumab 3 spartalizumab 2 olaparib 2 niraparib 2 Taxes 2 Methotrexate 2 Medroxyprogesterone Acetate 2 Imiquimod 2 Gemcitabine 2 Doxorubicin 2 trametinib 1 sintilimab 1 saracatinib 1 pegfilgrastim 1 netupitant, palosentron drug combination 1 navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1 mirabegron 1 masitinib 1 durvalumab 1 dostarlimab 1 dabrafenib 1 cobimetinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07319429 2026-03-13

FEMUS

Fudan University

Phase 2/3 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡